The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells

被引:29
|
作者
Salameh, A
Schomecker, G
Breitkopf, K
Dhein, S
Klaus, W
机构
[1] Institut für Pharmakologie, Universität zu Köln, 50931 Köln
关键词
endothelium; calcium; Fura-2; nitrendipine; dihydropyridines; nitric oxide;
D O I
10.1111/j.1476-5381.1996.tb15622.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Nitrendipine induces NO-release from coronary vascular endothelium presumably by activating endothelial NQ-synthase. We have investigated whether this effect may be mediated by an influence on the intracellular calcium in endothelial cells. 2 Bovine aortic endothelial cells (BAEC) were incubated with Fura-2/AM (1 mu M) for 30 min and Fura-2 fluorescence was measured at 510 nm in response to chopped excitation with both 340 and 380 nm. The ratio 340/380 nm (known to reflect changes in intracellular calcium) was calculated from these data. 3 Nitrendipine (0.1 to 100 mu M) led to a significant, concentration-dependent, monophasic increase in [Ca2+](i) in suspended BAEC by 11 +/- 2 nM (0.1 mu M), 23 +/- 3 nM (1 mu M), 34 +/- 4 nM (10 mu M) and by 47 +/- 5 nM (100 mu M) from a control level of 118 +/- 10 nM. 4 This elevation of intracellular calcium was prevented by pretreatment of BAECs with gadolinium (100 mu M) or by incubation with calcium free saline solution. In contrast, the application of 0.3 mu M thapsigargin did not abolish the nitrendipine-induced calcium signal. In additional experiments it was shown that the nitrendipine-induced NO-release (as measured with the oxy-haemoglobin-method could also be inhibited by gadolinium and was absent in calcium-free solution. 5 Thus, nitrendipine elevates intracellular calcium in suspended BAECs in a concentration-dependent manner. This elevation is mainly due to a gadolinium-sensitive calcium influx from the extracellular space rather than a calcium release from intracellular stores.
引用
收藏
页码:1899 / 1904
页数:6
相关论文
共 50 条
  • [1] ANTIHYPERTENSIVE THERAPY WITH THE CALCIUM-ANTAGONIST NITRENDIPINE
    ZAHRINGER, J
    BLANKE, R
    HERZ KREISLAUF, 1991, 23 (11): : 377 - 383
  • [2] INFLUENCE OF THE CALCIUM-ANTAGONIST NITRENDIPINE ON THE HEPATOTOXIC EFFECT OF CYCLOSPORINE-A
    ZOTZ, RB
    BESTE, M
    BREUER, N
    GOEBELL, H
    PHILIPP, T
    WAGNER, K
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 18 : S82 - S83
  • [3] SALIDIURETIC ACTION OF THE CALCIUM-ANTAGONIST NITRENDIPINE IN DOGS
    FUKUI, K
    TAMAKI, T
    YAMAMOTO, A
    SHOJI, T
    FUJISAWA, Y
    IWAO, H
    ABE, Y
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1987, 336 (05) : 572 - 577
  • [4] EXPERIENCE WITH NITRENDIPINE - A NEW CALCIUM-ANTAGONIST - IN HYPERTENSION
    ANDREN, L
    HANSSON, L
    ORO, L
    RYMAN, T
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1982, 4 : S387 - S391
  • [5] EFFECT OF CALCIUM-ANTAGONIST NITRENDIPINE ON THE INHALATIVE PROVOCATION WITH SOLUTIONS OF VARIED OSMOLARITY
    OVERLACK, A
    KLEINE, K
    MAGNUSSEN, H
    ATEMWEGS-UND LUNGENKRANKHEITEN, 1986, 12 (06) : 269 - 270
  • [6] ANTIHYPERTENSIVE THERAPY WITH THE LONG-ACTING CALCIUM-ANTAGONIST NITRENDIPINE
    MULLER, FB
    BOLLI, P
    ERNE, P
    BLOCK, LH
    KIOWSKI, W
    BUHLER, FR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1984, 6 : 1073 - 1076
  • [7] POSSIBLE ADDUCT FORMATION BETWEEN GLUTATHIONE AND NITRENDIPINE, A CALCIUM-ANTAGONIST
    NUNEZVERGARA, LJ
    DELAFUENTE, J
    SQUELLA, JA
    BOLETIN DE LA SOCIEDAD CHILENA DE QUIMICA, 1990, 35 (04): : 323 - 330
  • [8] ALTERED PHOSPHOINOSITIDE METABOLISM BY AN INTRACELLULAR CALCIUM-ANTAGONIST
    KNAUSS, TC
    CLINICAL RESEARCH, 1984, 32 (04): : A741 - A741
  • [9] THE CONCENTRATION AND EFFECT OF A NOVEL CALCIUM-ANTAGONIST, FELODIPINE, IN NORMAL SUBJECTS
    ELBAHIE, N
    ALLEN, E
    HILL, TWK
    EDGAR, B
    ROUTLEDGE, PA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 17 (05) : P637 - P638
  • [10] INTRACELLULAR-LOCALIZATION OF THE CALCIUM-ANTAGONIST AND CALMODULIN ANTAGONIST FENDILINE
    WEYHENMEYER, R
    GROSS, M
    MAURERSCHULTZE, B
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1989, 39-1 (02): : 199 - 201